Related Experiment Video
Updated: Aug 15, 2026
07:17
Murine Hind Limb Long Bone Dissection and Bone Marrow Isolation
Published on: April 14, 2016
Preclinical perspectives on bisphosphonate renal safety
Jean-Jacques Body1, Thomas Pfister, Frieder Bauss
1Institut Jules Bordet, Université Libre de Bruxelles, 1 Rue Héger-Bordet, 1000 Brussels, Belgium. jj.body@bordet.be
The Oncologist
|November 3, 2005
Summary
Cancer patients with renal insufficiency require careful bisphosphonate selection. Differences in bisphosphonate safety profiles exist, necessitating further research into renal toxicity risks and pharmacokinetic factors for optimal treatment choices.
Area of Science:
- Nephrology
- Oncology
- Pharmacology
Background:
- Renal insufficiency is common in cancer patients, often exacerbated by nephrotoxic cancer treatments.
- Intravenous bisphosphonates, used for metastatic bone disease, carry a risk of renal toxicity.
- Patient management requires balancing bisphosphonate efficacy with potential renal harm.
Purpose of the Study:
- To evaluate the renal safety profiles of different bisphosphonates in cancer patients.
- To compare the risk of renal deterioration associated with various bisphosphonate agents.
- To explore the influence of pharmacokinetic properties on bisphosphonate-induced renal toxicity.
Main Methods:
- Review of clinical data and preclinical studies on bisphosphonate renal safety.
- Comparative analysis of histopathologic damage and cumulative toxicity from bisphosphonate dosing.
- Investigation of pharmacokinetic factors like renal tissue half-life and protein binding.
Main Results:
- Occasional renal toxicity has been reported with some intravenous bisphosphonates.
- Preclinical studies indicate significant variations in renal safety among different bisphosphonates.
- Comparative studies reveal differences in histopathologic damage and cumulative toxicity potential.
Conclusions:
- Bisphosphonate choice for cancer patients with metastatic bone disease must consider renal safety alongside efficacy.
- Pharmacokinetic properties may explain observed differences in bisphosphonate renal safety.
- Further preclinical research is essential to fully understand and quantify bisphosphonate renal risks.
Related Concept Videos
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:27Urinary Tract Calculi IV: Nutrition Therapy and Prevention
Management of renal calculi focuses on effective strategies like tailored nutrition and hydration therapy. Adjusting diet and fluid intake reduces stone formation and recurrence, making these interventions simple yet powerful in kidney stone prevention and management.Understanding Kidney StonesKidney stones form when calcium, oxalate, uric acid, and cystine concentrate and crystallize in urine. Factors contributing to their formation include genetic predisposition, certain medical conditions,...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:24Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...